BPC-157 Dosing in Hepatic Impairment: Evidence, Risks, and Clinical Guidance At a glance No FDA-approved formulation / BPC-157 is available only through 503A compounding pharmacies Zero published human RCTs evaluating BPC-157 in hepatic impairment populations Animal models show hepatoprotective effects against NSAID, alcohol, and toxin-induced liver damage Standard compounded dose range is 200-500 mcg/day subcutaneously or intramuscularly Suggested starting dose in hepatic impairment is 200-250 mcg/day subcutaneously Peptides are cleared primarily by proteolytic degradation, not hepatic CYP450 metabolism Liver enzyme monitoring (ALT, AST, bilirubin) recommended at baseline and every 2-4 weeks BPC-157 has shown cytoprotective effects on gastric and intestinal mucosa in over 20 animal studies The FDA has not established hepatic dosing adjustments for BPC-157 Cycle length in liver-compromised patients: 4-6 weeks with reassessment before continuation What Is BPC-157 and How Does It Work
Step 1: Enter Vial Strength Input the total amount of BPC-157 in the vial, such as 5 mg or 10 mg
Complete BPI (also called a panplexus injury) In this type, all parts of the brachial plexus are involved in the injury
Pickart et al
BPI injuries lead to muscle loss, numbness down the arm, and sometimes severe pain
The prevalence of Baker's cysts in patients with symptomatic knee pain is estimated at around 5%10%, making it one of the most common culprits
